Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase 2 Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

NCT03050866 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT03050866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03050866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase 2 Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
Lead sponsor
Erasmus Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
February 21, 2017
Completion date
August 19, 2022
Enrollment
140 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor cell, metastatic prostate cancer